The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Homenko Ju.G.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Susin D.S.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Kataeva G.V.

Institut mozga cheloveka im. N.P. Bekhterevoĭ RAN, Sankt-Peterburg

Irishina Ju.A.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Zavolokov I.G.

N. Bekhtereva Institute of the Human Brain of the Russian Academy of Science, St. Petersburg, Russia

Characteristics of cerebral glucose metabolism in patients with cognitive impairment in Parkinson’s disease

Authors:

Homenko Ju.G., Susin D.S., Kataeva G.V., Irishina Ju.A., Zavolokov I.G.

More about the authors

Read: 2654 times


To cite this article:

Homenko JuG, Susin DS, Kataeva GV, Irishina JuA, Zavolokov IG. Characteristics of cerebral glucose metabolism in patients with cognitive impairment in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(5):46‑51. (In Russ.)
https://doi.org/10.17116/jnevro20171175146-51

Recommended articles:
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35

References:

  1. Levin OS, Fedorova NV. Parkinson's Disease. M.: MedPress-inform; 2014. (In Russ.)
  2. Hartmann A, Agid Y, Schapira A. What is Parkinson’s disease? From pathophysiology to symptoms. In: Parkinsonian Disorders in Clinical Practice. Eds. Schapira A., Hartmann A., Y Agid. Willey-Blackwell. 2008;1-39.
  3. Lewy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K. Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Dis. 2002;17(6):1221-1226. doi:10.1002/mds.10280
  4. Yakhno NN, Zakharov VV, Lokshina AB, Koberskaya NN, Mkhitaryan EA. Dementias. Guidelines for Physicians. M.: Medpress-inform; 2011. (In Russ.).
  5. Skoromets AA, Timofeyeva AA, Aliyev KT, Biletsky PS, Lalayan TV, Skoromets AP, Skoromets TA, Smolko DG, Khlynina SV. Cognitive functions in Parkinsons disease and parkinsonism: effects of Pronoran. Effective farmacotherapy. 2014;17:6-14. (In Russ.).
  6. Stanzhevsky AA, Tyutin LA, Litvinenko IV. The application of positron emission tomography in Parkinson's disease diagnosis. Diagnostic radiology and radiotherapy. 2010;3(1):12-19. (In Russ.).
  7. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S, Fahn S. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994;14:783-801. doi:10.1038/jcbfm.1994.99
  8. Carbon M, Edwards C, Eidelberg D. Functional brain imaging in Parkinson's disease. Adv Neurol. 2003;91:175-181.
  9. Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp. 2004;22:236-245. doi:10.1002/hbm.20033
  10. Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, Feigin A, Eidelberg D. Network modulation in the treatment of Parkinson's disease. Brain. 2006;129(10):2667-2678. doi:10.1093/brain/awl162
  11. Trošt M, Su S, Su PC, Yen R-F, Tseng H-M, Barnes A, Ma Y, Eidelberg D. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuro Image. 2006;31:301-307. doi:10.1016/j.neuroimage.2005.12.024
  12. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage. 2007;34(2):714-723. doi:10.1016/j.neuroimage.2006.09.003
  13. Medvedev SV, Skvortsova TYu, Krasikova RN. PET in Russia: positron emission tomography in clinics and physiology. 2008;318. (In Russ.).
  14. Nobili F, Morbelli S, Arnaldi D, Ferrara M, Campus C, Brugnolo F, Mazzei D, Mehrdad N, Sambuceti G, Rodriguez G. Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD). Journal of the Neurological Sciences. 2011;310(1):31-35. doi:10.1016/j.jns.2011.06.053
  15. Wichmann T, DeLong MR. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci. 2003;991:199-213. doi:10.1111/j.1749-6632.2003.tb07477.x
  16. Marié RM, Barre L, Dupuy B, Viader F, Defer G, Baron JC. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci. Lett. 1999;260:77-80. doi:10.1016/s0304-3940(98)00928-8
  17. Brück A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry. 2004;75:1467-1469. doi:10.1136/jnnp.2003.031237
  18. Mattis S. Mental state examination for organic mental syndrome in the elderly patients. Geriatric Psychiatry. Ed Bellack. L., Karasu T.B. N.Y.: Grune and Stratton; 1976.
  19. Petersen RS, Touchon J. Consensus on mild cognitive impairment. Research and practice in Alzheimer’s disease, E.A.D.C/A.D.C.S. Joint meeting. 2005;10:24-32.
  20. Talairach J, Tournoux P. Co-planar Stereotactic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging. Thieme New-York. 1988.
  21. Statistical Parametric Mapping. URL: www.fil.ion.ucl.ac.uk/spm/ (27.10.2016).
  22. WFU PickAtlas. URL: http://www.nitrc.org/projects/wfu_pickatlas/ (27.10.2016).
  23. Kataeva GV, Korotkov AD, Melnichuk KV. Patterns of Relative Evaluations of a Regional Cerebral Blood Flow and Cerebral Metabolism of Glucose in a Brain of a Normal Person. Meditsinskaya visualisatsia. 2007;2:84-92. (In Russ.).
  24. Yakushev I, Landvogt C, Buchholz HG, Fellgiebel A, Hammers A, Scheurich A, Schmidtmann I, Gerhard A, Schreckenberger M, Bartenstein P. Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res. 2008;164(2):143-153. doi:10.1016/j.pscychresns.2007.11.004
  25. Van Laere K, Santens P, Bosman T, De Reuck J, Mortelmans L, Dierck R. Statistical parametric mapping of 99mTc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med. 2004;24:933-942. doi:10.1007/s00259-002-1009-9
  26. Lee PH, Yong SW, An Y-S. Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholisterase inhibitor therapy. J Nucl Med. 2008;49:2006-2011. doi:10.2967/jnumed.108.054668
  27. Green J, McDonald WM, Vitek JL, Evatt M, Freeman A, Haber M, Bakay RAE, Triche S, Sirockman B, DeLong MR. Cognitive impairments in advanced PD without dementia. Neurology. 2002;59:1320-1324. doi:10.1212/01.wnl.0000031426.21683.e2
  28. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, Hyde TM, Weinberger DR. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol. 2002;51:156-164. doi:10.1002/ana.10078
  29. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006;30:1-23. doi:10.1016/j.neubiorev.2005.03.024
  30. Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain. 2015;138:1454-1476. doi:10.1093/brain/awv104
  31. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer’s disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60:1745-1748. doi:10.1001/archneur.60.12.1745

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.